Literature DB >> 21475424

What is the Role of Midodrine in Patients with Decompensated Cirrhosis?

Klara Werling1, Naga Chalasani.   

Abstract

Entities:  

Year:  2011        PMID： 21475424      PMCID： PMC3061021     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  13 in total

1.  Prevention of paracentesis-induced circulatory dysfunction: midodrine vs albumin. A randomized pilot study.

Authors:  Beate Appenrodt; Andrea Wolf; Frank Grünhage; Jonel Trebicka; Michael Schepke; Christian Rabe; Frank Lammert; Tilman Sauerbruch; J Heller
Journal:  Liver Int       Date:  2008-04-11       Impact factor: 5.828

2.  Beneficial effect of midodrine in hypotensive cirrhotic patients with refractory ascites.

Authors:  Achuthan Sourianarayanane; David S Barnes; Arthur J McCullough
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-02

3.  Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide.

Authors:  P Angeli; R Volpin; G Gerunda; R Craighero; P Roner; R Merenda; P Amodio; A Sticca; L Caregaro; A Maffei-Faccioli; A Gatta
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

4.  The effects of midodrine on the natriuretic response to furosemide in cirrhotics with ascites.

Authors:  V L Misra; R Vuppalanchi; D Jones; M Hamman; P Y Kwo; C Kahi; N Chalasani
Journal:  Aliment Pharmacol Ther       Date:  2010-10       Impact factor: 8.171

5.  Effects of a 7-day treatment with midodrine in non-azotemic cirrhotic patients with and without ascites.

Authors:  Georgios Kalambokis; Andreas Fotopoulos; Michalis Economou; Konstantinos Pappas; Epameinondas V Tsianos
Journal:  J Hepatol       Date:  2006-11-10       Impact factor: 25.083

Review 6.  The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.

Authors:  Richard Moreau; Didier Lebrec
Journal:  Hepatology       Date:  2006-03       Impact factor: 17.425

7.  Compensated cirrhosis: natural history and prognostic factors.

Authors:  P Ginés; E Quintero; V Arroyo; J Terés; M Bruguera; A Rimola; J Caballería; J Rodés; C Rozman
Journal:  Hepatology       Date:  1987 Jan-Feb       Impact factor: 17.425

8.  The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study.

Authors:  Puneeta Tandon; Ross T Tsuyuki; Lesley Mitchell; Michael Hoskinson; Mang M Ma; Winnie W Wong; Andrew L Mason; Klaus Gutfreund; Vincent G Bain
Journal:  Liver Int       Date:  2008-05-19       Impact factor: 5.828

9.  Midodrine versus albumin in the prevention of paracentesis-induced circulatory dysfunction in cirrhotics: a randomized pilot study.

Authors:  Virendra Singh; Prashant C Dheerendra; Baljinder Singh; Chander K Nain; Divya Chawla; Navneet Sharma; Ashish Bhalla; Sushil K Mahi
Journal:  Am J Gastroenterol       Date:  2008-06       Impact factor: 10.864

10.  Acute effects of the oral administration of midodrine, an alpha-adrenergic agonist, on renal hemodynamics and renal function in cirrhotic patients with ascites.

Authors:  P Angeli; R Volpin; D Piovan; A Bortoluzzi; R Craighero; S Bottaro; G F Finucci; E Casiglia; A Sticca; R De Toni; L Pavan; A Gatta
Journal:  Hepatology       Date:  1998-10       Impact factor: 17.425
View more
  2 in total

1.  Refractory ascites-the contemporary view on pathogenesis and therapy.

Authors:  Beata Kasztelan-Szczerbinska; Halina Cichoz-Lach
Journal:  PeerJ       Date:  2019-10-15       Impact factor: 2.984

2.  Chronic renal dysfunction in cirrhosis: A new frontier in hepatology.

Authors:  Ramesh Kumar; Rajeev Nayan Priyadarshi; Utpal Anand
Journal:  World J Gastroenterol       Date:  2021-03-21       Impact factor: 5.742
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.